Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR1 W4C FGFR1 amp |
| Therapy | Lucitanib |
| Indication/Tumor Type | estrogen-receptor positive breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 W4C FGFR1 amp | estrogen-receptor positive breast cancer | predicted - sensitive | Lucitanib | Preclinical - Pdx | Actionable | In a preclinical study, Lucitanib (E-3810) treatment resulted in reduced tumor volume in an ER-positive breast cancer patient-derived xenograft (PDX) model harboring FGFR1 W4C and FGFR1 amplification (PMID: 34593528). | 34593528 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34593528) | High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. | Full reference... |